ARCHIVES

Clinical Trials: ECOG Says Results In Metastatic disease equivalent, Unlikely To change Over Time

This article is from The Cancer Letter archive.

Vol. 25 No. 15 | April 16, 1999

Download PDF Visit The Full Archive

Related Articles

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006

NCI, NHGRI plan $100-million, three-year feasibility test for cancer genome project. NCI to establish biospecimen office.

September 23, 2005

EPIC, PLCO Studies Show High Fiber Diet Cuts Cancer Risk

May 2, 2003

Cancer Letter Editor Finalist for Loeb Award

May 16, 2003

US Oncology Clarifies Role of Pharmacy Committee

January 24, 2003

Canadian Products Anticancer Drugs In Plant Culture

April 22, 1983